LGM
ATXS

Logos Global Management’s Astria Therapeutics ATXS Stock Holding History

Logos Global Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,000,000
Closed -$14.1M – 59
2024
Q1 		$14.1M Buy
+1,000,000
New +$12.5M 1.14% 26

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Logos Global Management's ATXS Position: Q4 2025 in Review

Logos Global Management sold out of Astria Therapeutics (ATXS) in Q4 2025, closing a stake of 500,000 shares — an estimated $3.64M sold.

Logos Global Management first reported a position in ATXS in Q2 2021 and held it in 13 quarters. The position peaked at $17.5M in Q1 2024. 141 funds tracked by Wall St. Rank hold ATXS as of Q4 2025.

  • Logos Global Management reported no remaining Astria Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Logos Global Management sold 500,000 Astria Therapeutics shares in Q4 2025, an estimated $3.64M.
  • Logos Global Management first reported a position in Astria Therapeutics in Q2 2021 and held it in 13 quarters.
  • Logos Global Management's Astria Therapeutics position peaked at $17.5M in Q1 2024.
  • 141 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2025.

Based on Logos Global Management's 13F filing for Q4 2025, filed 17 Feb 2026.